Skip to main content

Drug Interactions between minoxidil / progesterone / tretinoin topical and silodosin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

minoxidil topical silodosin

Applies to: minoxidil / progesterone / tretinoin topical and silodosin

MONITOR: Theoretically, topical administration of minoxidil may potentiate the hypotensive effects of systemic minoxidil and other vasodilators. Although systemic absorption of topical minoxidil is generally minimal (approximately 1.6% to 3.9% of an applied dose), adverse cardiovascular effects such as edema, palpitations, blood pressure decreases, and increased pulse rate have been reported in a few patients. Increased systemic absorption may occur when topical minoxidil is used in excess of normally recommended dosages or applied to compromised skin.

MANAGEMENT: Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.

References (2)
  1. Leenen FH, Smith DL, Unger WP (1988) "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol, 26, p. 481-5
  2. (2002) "Product Information. Rogaine (minoxidil topical)." Johnson and Johnson/McNeil Consumer

Drug and food interactions

Moderate

silodosin food

Applies to: silodosin

ADJUST DOSING INTERVAL: Food may reduce the oral bioavailability of silodosin. The effect of a moderate-fat, moderate-calorie meal on silodosin pharmacokinetics was variable and decreased silodosin maximum plasma concentration (Cmax) by approximately 18% to 43% and systemic exposure (AUC) by 4% to 49% across three different studies. The maximum effect of food (i.e., coadministration with a high-fat, high-calorie meal) on the pharmacokinetics of silodosin was not evaluated. Safety and efficacy clinical trials for silodosin were always conducted in the presence of food intake.

MANAGEMENT: Patients should be instructed to take silodosin with a meal to reduce the risk of adverse events.

References (1)
  1. (2008) "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer